Release date: 2017-03-24 The treatment of recurrent lung cancer is a challenge for both doctors and patients, because patients with lung cancer recurrence are usually not suitable for surgery, and the effects of radiation accumulation on important tissues around the tumor (such as heart, healthy lung tissue, esophagus) are also limited. Radical radiotherapy has been used in patients with recurrent lung cancer who have received radiation therapy. Therefore, palliative treatment has become a common treatment for patients with lung cancer recurrence. The main purpose is to relieve pain and relieve symptoms. A number of studies have previously confirmed that proton therapy can be used for recurrent radiotherapy of recurrent tumors because of its Bragg peak advantage. At the multi-disciplinary seminar on thoracic tumors, Professor Zhang Yuxi, as the first author of the study of Senior Author and Dr. Jennifer Ho, confirmed the conformal intensity-modulated proton radiation therapy (IMPT) for the first time. It can safely and effectively treat patients with lung cancer recurrence, prolong survival, and significantly reduce treatment-related toxicity. This is the first and only IMPT re-radiation-related study of chest tumors with the largest number of samples. "Treatment of patients who have undergone chest radiotherapy in the past is a situation that clinicians often encounter. How to enable patients to receive large enough radiation doses to eliminate new tumors without causing serious damage to the patient's healthy tissue is a clinician. "One of the challenges," said Jennifer Ho, MD, a radiation oncology resident at the MD Anderson Cancer Center. "The first of our studies confirms that IMPT can safely and effectively treat these patients without prematurely increasing the risk of serious toxicity. Improve patient local control rate. " “In the past, 20%-30% of patients had moderate to severe or even fatal side effects after receiving re-radiation. We know that using IMPT technology can get a more accurate treatment plan and better protect healthy tissues, but we It is uncertain whether this advantage of IMPT technology can be translated into better clinical efficacy.†Professor Zhang Yuxi, a professor of radiation oncology at the MD Anderson Cancer Center in the United States, said, “ Our findings confirm other types of radiation. Compared with the treatment method, the use of IMPT technology (re-radiation therapy for patients with lung cancer recurrence) can achieve better local control rate and survival rate, and the toxicity is small, indicating that IMPT is an ideal treatment for patients with chest tumor recurrence. " Source: Proton China Shenzhen Sunson Tech Co., Ltd , https://www.sunsonkiosk.com